RNA interference: potential therapeutic targets - PubMed (original) (raw)

Review

RNA interference: potential therapeutic targets

S Jana et al. Appl Microbiol Biotechnol. 2004 Nov.

Abstract

One of the most exciting findings in recent years has been the discovery of RNA interference (RNAi). RNAi methodologies hold the promise to selectively inhibit gene expression in mammals. RNAi is an innate cellular process activated when a double-stranded RNA (dsRNA) molecule of greater than 19 duplex nucleotides enters the cell, causing the degradation of not only the invading dsRNA molecule, but also single-stranded (ssRNAs) RNAs of identical sequences, including endogenous mRNAs. The use of RNAi for genetic-based therapies has been widely studied, especially in viral infections, cancers, and inherited genetic disorders. As such, RNAi technology is a potentially useful method to develop highly specific dsRNA-based gene-silencing therapeutics.

PubMed Disclaimer

Similar articles

• Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
  DeVincenzo JP. DeVincenzo JP. Early Hum Dev. 2009 Oct;85(10 Suppl):S31-5. doi: 10.1016/j.earlhumdev.2009.08.013. Epub 2009 Oct 14. Early Hum Dev. 2009. PMID: 19833462
• RNAi: gene-silencing in therapeutic intervention.
  Shuey DJ, McCallus DE, Giordano T. Shuey DJ, et al. Drug Discov Today. 2002 Oct 15;7(20):1040-6. doi: 10.1016/s1359-6446(02)02474-1. Drug Discov Today. 2002. PMID: 12546893 Review.
• RNA interference in neuroscience.
  Genc S, Koroglu TF, Genc K. Genc S, et al. Brain Res Mol Brain Res. 2004 Dec 20;132(2):260-70. doi: 10.1016/j.molbrainres.2004.02.004. Brain Res Mol Brain Res. 2004. PMID: 15582163 Review.
• RNA interference and its current application in mammals.
  Shen WG. Shen WG. Chin Med J (Engl). 2004 Jul;117(7):1084-91. Chin Med J (Engl). 2004. PMID: 15265387 Review.
• RNA interference strategies as therapy for respiratory viral infections.
  DeVincenzo JP. DeVincenzo JP. Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S118-22. doi: 10.1097/INF.0b013e318168b759. Pediatr Infect Dis J. 2008. PMID: 18820571

Cited by

• Illuminating the gateway of gene silencing: perspective of RNA interference technology in clinical therapeutics.
  Sindhu A, Arora P, Chaudhury A. Sindhu A, et al. Mol Biotechnol. 2012 Jul;51(3):289-302. doi: 10.1007/s12033-011-9456-9. Mol Biotechnol. 2012. PMID: 21947958 Free PMC article. Review.
• EMMPRIN reduction via scFv-M6-1B9 intrabody affects α3β1-integrin and MCT1 functions and results in suppression of progressive phenotype in the colorectal cancer cell line Caco-2.
  Sangboonruang S, Thammasit P, Intasai N, Kasinrerk W, Tayapiwatana C, Tragoolpua K. Sangboonruang S, et al. Cancer Gene Ther. 2014 Jun;21(6):246-55. doi: 10.1038/cgt.2014.24. Epub 2014 Jun 13. Cancer Gene Ther. 2014. PMID: 24924201
• Nonviral methods for siRNA delivery.
  Gao K, Huang L. Gao K, et al. Mol Pharm. 2009 May-Jun;6(3):651-8. doi: 10.1021/mp800134q. Mol Pharm. 2009. PMID: 19115957 Free PMC article. Review.
• Lipid-based vectors for siRNA delivery.
  Zhang S, Zhi D, Huang L. Zhang S, et al. J Drug Target. 2012 Nov;20(9):724-35. doi: 10.3109/1061186X.2012.719232. Epub 2012 Sep 20. J Drug Target. 2012. PMID: 22994300 Free PMC article. Review.
• shRNA transgenic swine display resistance to infection with the foot-and-mouth disease virus.
  Hu W, Zheng H, Li Q, Wang Y, Liu X, Hu X, Liu W, Liu S, Chen Z, Feng W, Cai X, Li N. Hu W, et al. Sci Rep. 2021 Aug 12;11(1):16377. doi: 10.1038/s41598-021-95853-3. Sci Rep. 2021. PMID: 34385528 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program